Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Ira Gantz"'
Autor:
Tongtong Wang, Shrita M. Patel, Anne Hickman, Xinyue Liu, Philip LStJ Jones, Ira Gantz, Carol E. Koro
Publikováno v:
Diabetes Therapy, Vol 11, Iss 3, Pp 711-723 (2020)
Abstract Introduction Based on post-marketing surveillance, concern has been raised that sodium–glucose cotransporter 2 inhibitors (SGLT2i) may increase the risk of necrotizing fasciitis of the perineum (Fournier’s gangrene, FG). As a result of t
Externí odkaz:
https://doaj.org/article/57a78bad45474da09e6cb960c8bf56c0
Autor:
Seung-Hwan Lee, Ira Gantz, Elizabeth Round, Melanie Latham, Edward A. O’Neill, Paulette Ceesay, Shailaja Suryawanshi, Keith D. Kaufman, Samuel S. Engel, Eseng Lai
Publikováno v:
BMC Endocrine Disorders, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background Type 2 diabetes (T2D) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease progression. Omarigliptin is a once-weekly dipeptidyl peptidase-4 inhib
Externí odkaz:
https://doaj.org/article/fd0f014490b14485887e0c37aef648d6
Autor:
Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Catherine Ntabadde, Sukrut Shah, Edward A. O’Neill, Samuel S. Engel, Keith D. Kaufman, Eseng Lai
Publikováno v:
Cardiovascular Diabetology, Vol 16, Iss 1, Pp 1-12 (2017)
Abstract Background Omarigliptin is a once-weekly (q.w.) oral DPP-4 inhibitor that is approved for the treatment of patients with type 2 diabetes mellitus (T2DM) in Japan. To support approval of omarigliptin in the United States, the clinical develop
Externí odkaz:
https://doaj.org/article/e1307a87bfbe4e15adca043c76c5ba45
Autor:
Jarl E. S. Wikberg, Jeffrey B. Tatro, Helgi Schiöth, Colin Pouton, Kathleen G. Mountjoy, Victor J. Hruby, Carrie Haskell-Luevano, Ira Gantz, Tung M. Fong, Sadaf Farooqi, Alex N. Eberle, Roger D. Cone, Adrian J. L. Clark, Biao-Xin Chai, Vanni Caruso
Publikováno v:
IUPHAR/BPS Guide to Pharmacology CITE. 2023
Melanocortin receptors (provisional nomenclature as recommended by NC-IUPHAR [41]) are activated by members of the melanocortin family (α-MSH, β-MSH and γ-MSH forms; δ form is not found in mammals) and adrenocorticotrophin (ACTH). Endogenous anta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8e1dd58e2809f3d3ee0d5953002ec11
https://doi.org/10.2218/gtopdb/f38/2023.1
https://doi.org/10.2218/gtopdb/f38/2023.1
Autor:
Samuel Dagogo‐Jack, Christopher P. Cannon, David Z. I. Cherney, Francesco Cosentino, Jie Liu, Annpey Pong, Ira Gantz, Robert Frederich, James P. Mancuso, Richard E. Pratley
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1245-1254
To assess selected cardiorenal outcomes with ertugliflozin according to use of baseline glucose-lowering agent.VERTIS CV was a cardiovascular (CV) outcome trial for ertugliflozin versus placebo, conducted in patients with type 2 diabetes and establis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8424c5e3728d5097ba0aa293273afa0
https://doi.org/10.1111/dom.14691
https://doi.org/10.1111/dom.14691
Autor:
Samuel Dagogo-Jack, Robert Frederich, Jie Liu, Christopher P Cannon, Harry Shi, David Z I Cherney, Francesco Cosentino, Urszula Masiukiewicz, Ira Gantz, Richard E Pratley
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism.
Context VERTIS CV evaluated the cardiovascular safety of ertugliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). Objective The aim of these analyses was to assess the insulin requirements of VERTIS CV patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae5cb90f0ed5fcfb1e6556fdb7f87ec7
https://doi.org/10.1210/clinem/dgac764
https://doi.org/10.1210/clinem/dgac764
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To assess the efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease (ASCVD) inadequately controlled by insulin. Materials and methods VERTIS CV was the cardiov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23d349ba6c2e76e2ee8df333d5579aad
https://doi.org/10.1111/dom.14385
https://doi.org/10.1111/dom.14385
Autor:
Ira Gantz, Timothy M. E. Davis, Robert Frederich, Jie Liu, Giuseppe Derosa, Matthew J. Budoff, Alexandra G. Palmer, David Lawrence
Publikováno v:
Diabetes Therapy
Introduction VERTIS CV is the cardiovascular outcome trial for the sodium–glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin. A sub-study was conducted to assess the efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::143fc5cb4b2f4e6b02672ae3a5bcdeec
https://doi.org/10.1007/s13300-021-01033-x
https://doi.org/10.1007/s13300-021-01033-x
Autor:
Miho Kameya, Tomona Hirano, Yutaka Seino, Nobuyuki Oshima, Samuel S. Engel, Taro Okamoto, Edward A. O'Neill, Ira Gantz, Takashi Kadowaki, Asako Sato, Kohei Kaku
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the efficacy and safety of adding the once‐weekly oral dipeptidyl peptidase‐4 inhibitor omarigliptin to treatment of Japanese patients with type 2 diabetes and inadequate glycaemic control on insulin monotherapy. Materials and Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1a96d68d978ceebe14be15b7750341
https://doi.org/10.1111/dom.14331
https://doi.org/10.1111/dom.14331
Autor:
Bernard Charbonnel, Weichung Shih, Ira Gantz, Richard E. Pratley, Samuel Dagogo-Jack, Francesco Cosentino, Darren K. McGuire, Urszula Masiukiewicz, Steven G. Terra, Robert Frederich, Nilo B. Cater, David Z.I. Cherney, James P. Mancuso, Christopher P. Cannon
Publikováno v:
Circulation
Supplemental Digital Content is available in the text.
Background: In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure (HHF). We assessed the effect of ertugli
Background: In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure (HHF). We assessed the effect of ertugli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3834ac9975ebc0d7ba73fa7a2e2e1a4b
https://doi.org/10.1161/circulationaha.120.050255
https://doi.org/10.1161/circulationaha.120.050255